A Phase 1 Study of KHN702 Tablets in Healthy Subjects
Status:
NOT_YET_RECRUITING
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, randomized, double-blind, placebo-controlled study divided into a Single Ascending Dose (SAD) stage and a Multiple Ascending Dose (MAD) phase. The primary objective is to evaluate the safety and tolerability of KHN702 tablets in Chinese healthy volunteersHVs).